Advancing the Standard of Care through Clinical Investigation
At our practice, we are dedicated to moving the field of podiatric medicine forward through rigorous clinical research. Dr. David Simon, DPM, FACFAS, serves as a lead investigator in major clinical trials, ensuring our patients have access to the latest innovations in biologic wound healing. To provide the highest level of patient safety and data integrity, our research program is supported by a dedicated clinical coordinator.
Featured Research: The STABLECAMP Trial
Dr. Simon has been an investigator for the STABLECAMP Trial for over a year. This multicenter, prospective, randomized controlled trial utilizes a “Matriarch” platform design to evaluate the efficacy of various Cellular, Acellular, and Matrix-like Products (CAMPs) against the standard of care for chronic wounds.
Key Findings from the Interim Analysis October 2025 Publication: This data, published in the International Journal of Tissue Repair, demonstrates the clinical impact of advanced amniotic allografts:
- Diabetic Foot Ulcers (DFU): Treatment with AmnioCore Pro (DLACG) resulted in a 91.18% average reduction in wound area. Overall, all tested tissue products showed a trend toward superiority over standard care alone.
- Venous Leg Ulcers (VLU): AmnioCore (DLAG) achieved a 50% complete closure rate in the interim analysis, reaching statistical significance compared to standard treatments.
Published Evidence: Retrospective Analysis of AmnioCore
In addition to ongoing trials, Dr. Simon co-authored a multicenter retrospective study evaluating the real-world performance of AmnioCore Amniotic Membranes. This research focused on the healing of chronic Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers.
Study Highlights:
- Wound Volume Reduction: The study confirmed that average wound volume decreased consistently over time across all three chronic wound categories when treated with AmnioCore.
- Clinical Versatility: The findings demonstrated successful outcomes in various treatment settings, including specialized wound clinics and hospital environments.
- Innovation in Care: This research characterizes AmnioCore as an effective biologic barrier that delivers essential growth factors on a structural protein matrix to facilitate healing.
Information for Prospective Participants
We are currently enrolling patients who meet the following general criteria:
- Chronic Wounds: Ulcers (DFU or VLU) present for 4 to 52 weeks.
- Wound Size: Ulcers measuring 1–5 cm² after professional debridement.
- Health Status: Adequate blood flow to the limb and manageable blood sugar levels (HbA1c < 12%).
For further information, please Contact our Clinical Coordinator today to see if you qualify.
